头颈癌患者血液学参数与PET/CT代谢参数的相关性
回顾性分析71例非转移性头颈鳞癌患者治疗前血液NLR、PLR与FDG-PET/CT代谢参数的相关性。PLR与MTV(rho=0.26,P=.03)和TLG(rho=0.28,P=.02)相关,但与SUV无关;NLR与所分析的PET/CT代谢参数均无相关性。TLG与较差的生存相关,NLR和PLR与OS和DSS相关。
要点
- 治疗前PLR与MTV(rho=0.26,P=.03)和TLG(rho=0.28,P=.02)相关,但与最大SUV或平均SUV无关。
- NLR与所分析的PET/CT代谢参数均无相关性。
- TLG与较差的生存相关,NLR和PLR与OS和DSS相关;作者认为需验证性研究。
核心结论
- 在未接受任何治疗(如根治性放化疗或肿瘤手术联合辅助放疗)的头颈鳞癌患者中,基线PLR与MTV和TLG相关,但与SUV无关。
- NLR与本研究所分析的任何PET/CT代谢参数均无相关性。
- 作者认为需要验证性研究,且肿瘤微环境、宿主炎症与FDG-PET/CT指标之间可能存在相互作用,值得进一步研究。
研究设计与样本
- 回顾性连续纳入接受治疗前PET/CT的头颈鳞癌患者,共分析71例。
- NLR和PLR使用任何治疗开始前10天内测量的全血细胞计数计算。
- 采用Spearman rho检验评估NLR和PLR与PET/CT代谢参数的相关性。
主要发现
- 1年、2年和3年总生存率分别为86%、76%和68%。
- PLR与MTV相关(rho=0.26,P=.03),与TLG相关(rho=0.28,P=.02),但与最大SUV或平均SUV无关。
- NLR与所分析的PET/CT代谢参数均无相关性。
- TLG在单因素和多因素分析中与较差的生存相关,但其他PET/CT代谢参数与OS或DSS均无关联。
- NLR和PLR在单因素和多因素分析中与OS和DSS相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要验证性研究。
- 作者认为肿瘤微环境、宿主炎症与FDG-PET/CT指标之间可能存在相互作用,值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic inflammation is predictive of the overall survival in cancer patients and is related to the density of immune cells in the tumor microenvironment of cancer, which in turn correlates with 18F -fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) metabolic parameters (MPs). The density of tumor-infiltrating lymphocytes (TILs) in the microenvironment has the potential to be a biomarker that can be used clinically to optimize patient selection in oropharyngeal head and neck squamous cell carcinoma (HNSCC). There is little to no data regarding the association of systemic inflammation with PET/CT-MPs, especially in HNSCC. This study aimed to evaluate the correlation between markers of host inflammation, namely blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), with the PET/CT-MPs standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor, derived from FDG-PET/CT in patients with nonmetastatic (cM0) HNSCC before treatment. We hypothesized that NLR and PLR at baseline are positively correlated with PET/CT-MPs. METHODS: A retrospective review of consecutive patients with HNSCC with a pretreatment PET/CT was performed. NLR and PLR were computed using complete blood counts measured within 10 days before the start of any treatment. The correlation between NLR and PLR with PET/CT-MPs was evaluated with Spearman's rho test. RESULTS: Seventy-one patients were analyzed. Overall survival (OS) at 1, 2, and 3 years was 86%, 76%, and 68%. PLR was found to be correlated with MTV (rho = 0.26, P = .03) and TLG (rho = 0.28, P = .02) but not with maximum SUV or mean SUV. There was no correlation between NLR and the analyzed PET/CT-MPs. TLG was associated with worse survival in uni- and multivariable analysis, but no other PET/CT-MPs were associated with either OS or disease-specific survival (DSS). NLR and PLR were associated with OS and DSS on uni- and multivariable analysis. CONCLUSIONS: In patients with HNSCC before any treatment such as definitive radio (chemo)therapy or oncologic surgery followed by adjuvant RT, baseline PLR correlated with MTV and TLG but not with SUV. NLR was not correlated with any PET/CT-MPs analyzed in our study. Confirmatory studies are needed, and a potential interaction between tumor microenvironment, host inflammation, and FDG-PET/CT measures warrants further investigation.
引用
- Bojaxhiu B, Sinovcic D, Elicin O, et al. Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer. Radiat Oncol. 2022. PMID: 35964056. doi:10.1186/s13014-022-02112-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。